Mupirocin (pseudomonic acid A), an antibiotic produced by Pseudomonasfluorescens, showed a high level of activity against staphylococci and streptococci and against certain gram-negative bacteria, including Haemophilus influenzae and Neisseria gonorrhoeae, but was much less active against most gram-negative bacilli and anaerobes. Nearly all clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis, including multiply resistant strains, were susceptible (mupirocin MIC, o0.5 ,ug/ml). There was no cross-resistance between mupirocin and clinically available antibiotics, and the selection of resistant variants in vitro occurred at a low frequency. Mupirocin was highly bound (95% bound) to the protein of human serum, and activity was reduced 10-to 20-fold in the presence of human serum. The activity of mupirocin was not greatly influenced by inoculum size but was significantly enhanced in acid medium. In tests of bactericidal activity, MBCs were 8-to 32-fold higher than MICs and the antibiotic demonstrated a slow bactericidal action in time-kill tests, resulting in 90 to 99% killing after 24 h at 37°C.
The isolation and characterization of a group of antibacterial substances produced by Pseudomonas fluorescens was reported by Fuller et al. (7) , and the name pseudomonic acid was ascribed to the major metabolite, which accounted for most of the antibacterial activity observed. Subsequent investigations revealed, in addition, the presence of three chemically related compounds as minor metabolites; for convenience, the substances were termed pseudomonic acids A (the major metabolite), B, C, and D (3) (4) (5) 11) (Fig. 1 ). More recently, the term mupirocin has been adopted as the approved name for pseudomonic acid A.
Pharmacokinetic studies in animals and in human volunteer subjects showed that mupirocin was well absorbed after oral and parenteral administration but serum antibiotic concentrations were short-lived as a result of extensive degradation to the antibacterially inactive metabolite, monic acid A (1; Beecham research laboratories, unpublished data), which is formed by hydrolysis of the ester linkage between the nucleus and the side chain of mupirocin (Fig. 1) . Accordingly, the studies reported here were designed to investigate the antibacterial properties of mupirocin as an antibiotic for topical usage.
MATERIALS AND METHODS Antibiotics. Mupirocin was used as the sodium salt in these studies. Standard antibiotics were obtained from the following manufacturers: benzylpenicillin, cloxacillin, and methicillin, Beecham Pharmaceuticals; erythromycin, Eli Lilly & Co.; fusidic acid, Leo Laboratories Ltd.; gentamicin, Nicholas Laboratories Ltd.; neomycin, the Upjohn Co.
Bacteria. Most of the cultures tested were clinical strains of bacteria isolated from infections of the skin and other sources.
MICs. Serial dilutions of mupirocin were added to 18-ml volumes of molten Mueller-Hinton agar (Difco Laboratories) in petri dishes. The medium was supplemented with horse blood for tests with streptococci (5% [vol/vol] for tests with Haemophilus influenzae. For tests with Propionibacterium spp. the antibiotic was incorporated into tryptone soy agar (Oxoid) containing 1.0% yeast extract and 0.5% Tween 80. When set, the agar was inoculated with 0.001 ml of an undiluted overnight broth (tryptone soy broth; Oxoid) culture of the test organism, an inoculum of approximately S x 105 cells. The plates were incubated at 37°C and examined after 18 h in the case of aerobic bacteria, after 24 h in 5% CO2 for the neisseriae, and after 48 to 72 h in 95% H2-5% CO2 in GasPak jars (BBL Microbiology Systems) for anaerobes. The MICs were determined as the lowest concentrations of antibiotic preventing visible growth.
The effects of changes in medium, size of inoculum, and pH of medium on the activity of mupirocin were measured. MICs of mupirocin were determined in blood agar base (Oxoid), diagnostic sensitivity test agar (Oxoid), Iso-Sensitest agar (Oxoid), and tryptone soy agar (Oxoid). The effect of pH was determnined by measurement of MICs in 2.0-ml volumes of Mueller-Hinton broth buffered over the pH range of 5.0 to 8.0, and the effect of change of inoculum size was determined in tests in Mueller-Hinton agar.
MBCs. Serial dilutions of mupirocin were prepared in tubes containing 2.0-ml volumes of Mueller-Hinton broth (Difco) which were inoculated with an overnight broth culture diluted to give an inoculum of approximately 5 x 105 cells per ml. After 18 h of incubation at 37°C, a 0.01-ml sample from each tube showing no visible growth was transferred onto antibiotic-free agar and incubated at 37°C overnight. The MBC was defined as the lowest concentration at which the count was reduced to five colonies or less, a reduction of 99.9% of the bacterial inoculum.
Serum binding and effect of serum on activity. Solutions of mupirocin were prepared in sterile pooled huiman serum buffered to pH 7.4 to give a concentration of 100 ,ug of antibiotic per ml of serum. After standing at room temperature for 1 h, the serum was subjected to centrifugal ultrafiltration through Amicon Centriflo CF5OA membrane cones. The concentration of antibiotic in the ultrafiltrate was determined by agar diffusion assay against aqueous 0.05 M phosphate buffer (pH 7.4) standard solutions with B. subtilis ATCC 6633 as the assay organism. (10-8 to 10-9) of colonies growing at concentrations of >8.0 ,ug of mupirocin per ml was similar to that observed in the cultures exposed to erythromycin and less than that seen in the plates containing fusidic acid. None of the colonies cultured showed evidence of cross-resistance. Effects of medium, pH, inoculum, and serum. The antibacterial activity of mupirocin was not influenced by the composition of the medium, and MICs against Staphylococcus aureus and Staphylococcus epidermidis were the same in Mueller-Hinton agar, blood agar base, diagnostic sensitivity test agar, Iso-Sensitest agar, and tryptone soy agar.
Similarly, changes in the size of inoculum used in serial dilution tests had little effect on the antibacterial activity of mupirocin, and there was a variation of only two-to fourfold in the MICs of mupirocin against three strains of Staphylococcus aureus for inocula ranging from approximately 5 x 105 to 5 cells.
On the other hand, the activity of mupirocin was affected by the pH of the medium, and the compound was notably more active in acid medium than in neutral or alkaline media. For instance, mupirocin was four-to eightfold more active at pH 6.0 than at pH 7.0, and, in turn, was twice as active at pH 7.0 than in medium buffered to pH 8.0 (Table 4) . The antibiotic was even more active at pH 5.0 and pH 5.5, although at the lower value, growth of the bacteria was diminished, which may have contributed to the greatly enhanced level of antibacterial activity demonstrated by mupirocin at this pH.
Mupirocin was highly bound (95%) to the protein of human serum, and as a consequence, the activity of the antibiotic was reduced in the presence of human serum. In general, the MICs of mupirocin were 10 to 20 times higher in tests in agar containing 50% human serum (MIC range, 2.5 to 5.0 ,ug/ml) than in serum-free agar (MIC range, 0.1 to 0.5 Bactericidal activity. In general, the MBCs of mupirocin against Staphylococcus aureus were 8-to 32-fold higher than the corresponding MICs. Thus, the MICs against nine test strains ranged from 0.12 to 1.0 p.g of mupirocin per ml and the MBCs ranged from 4.0 to 32 ,ug of mupirocin per ml.
The results of viable count studies to measure the bactericidal effects produced by mupirocin against staphylococci showed a similar pattern against all strains tested in that the antibiotic caused an inhibition of growth during the initial period of the test which was followed by a period of bactericidal activity, resulting in a 90 to 99% reduction in bacterial numbers at 24 h.
DISCUSSION
The results reported here show that mupirocin was highly active against streptococci and staphylococci, the organisms responsible for most common bacterial infections of the skin. The relatively low order of activity demonstrated against normal members of the skin flora such as corynebacteria, micrococci, and the anaerobic Propionibacterium spp. may also be an important feature of the antibacterial spectrum of mupirocin as the presence of these organisms is considered to contribute to the normal defense mechanisms against infections (13, 14) . Additionally, the enhanced activity of mupirocin in acid milieu may well be advantageous in relation to the acid pH associated with skin and its environment.
Other important criteria for a topical antibiotic are that its use should not lead to the rapid emergence of resistant bacteria, nor should there be cross-resistance with other antibiotics, particularly those of importance in the treatment of serious systemic infections. Mupirocin was active against nearly all strains of coagulase-positive and coagulase-negative staphylococci tested, including multiply resistant isolates, but three clinical strains of staphylococci with reduced susceptibility to mupirocin were identified. There was no evidence of cross-resistance between mupirocin and any of the clinically available antibiotics investigated, in agreement with the findings of others who have reported the activity of mupirocin against multiply resistant staphylococci (2, 6, 15) .
In addition, the rate of emergence of mupirocin-resistant staphylococci in in vitro studies was slow, and these variants showed no cross-resistance with other antibiotics. The absence of cross-resistance between mupirocin and other groups of antibiotics is not altogether unexpected in view of the unique chemical structure and novel mode of action, inhibition of isoleucyl-tRNA synthetase, which is different from that of any available antibiotic (8) (9) (10) 
